Black Diamond Therapeutics Inc. Common Stock (BDTX)

FairStock Score: 78/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earning power and a margin of safety. Black Diamond is a clinical-stage oncology company with 21 employees, no approved product, and a lead candidate, silevertinib, in Phase 2 for EGFR mutant lung cancer and glioblastoma. Filings show a puzzling history: fiscal 2025, ended 2025-12-31, produced revenue of $70.0M, net income of $22.4M, and EPS of $0.39, after fiscal 2024 net loss of $69.7M and fiscal 2023 net loss of $82.4M. That fits the computed TURNAROUND label, but recent quarters are not confirming it: fiscal Q1 2026, ended 2026-03-31, lost $9.0M, or $0.16 per diluted share, and fiscal Q2 2026, ended 2026-06-30, lost $9.9M, or $0.17 per diluted share. Trailing free cash flow is -$32.8M, a -34.0% FCF yield. At the 2026-10-13 close of $1.68, FairStock calculations show market cap of $96.5M, P/B of 1.01, P/E of -2.24, ROE of -37.21%, ROCE of -19.11%, and D/E of 0.18. The Piotroski F-Score of 1/9 and Altman Z-Score of -0.46 signal fragility. The FairStock Score is 78/100, but biotech value ultimately depends on trial outcomes, not book value. Without an approved product or a clear moat, I see speculative optionality, not a Graham-style bargain. I would want durable revenue, controlled cash burn, and a wider discount to liquidation value before calling it safe.

In plain English: Black Diamond Therapeutics is a very small clinical-stage cancer drug developer with 21 employees and no approved product. It reported a profit in fiscal 2025, but recent quarters show it is losing money again and burning cash, so the business looks fragile. The stock trades near the value of its stated net assets, but that low price reflects high risk rather than a proven bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer